1. Flasshove M, Banerjee D, Leonard JP, Mineishi S, Li MX, Bertino JR, Moore MA. Retroviral transduction of human CD34 + umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum Gene Ther 1998; 9: 63-71.

2. Wang G, Weiss C, Sheng P, Bresnick E. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransfer-ase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem Pharmacol 1996; 51:1221-1228.

3. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29:607-649.

4. D'Hondt V, Caruso M, Bank A. Retrovirus-mediated gene transfer of the multidrug resistance-associated protein (MRP) cDNA protects cells from chemotherapeutic agents. Hum Gene Ther 1997; 8:1745-1751.

5. Gottesman MM, Fojo AT, Bates SE. Multidrug-resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2002; 2: 48-58.

6. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Bio-chem 1993; 62:385-427.

7. Deeley RG, Cole SP. Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 1997; 8: 193-204.

8. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71:537-92.

9. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug reistance. J Bioenerg Biomemr 2001; 6:503-511.

10. Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency and toxicity. Cancer Res 1991a; 51:5417-5424.

11. Galski H, Sullivan M, Willingham MC, Chin K-V, Gottesman MM, Pastan I, Merlino GT. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin induced leukopenia. Mol Cell Biol 1989; 9:4357-4363.

12. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice which express the human multidrug resistance gene in bone marrow enable a rapid identification of agents which reverse drug resistance. Proc Natl Acad Sci USA 1991b; 88:547-551.

13. Mickisch GH, Aksentijevich I, Schoenlein PV, Goldstein LJ, Galski H, Staehle C, Sachs DH, Pastan I, Gottesman MM. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992; 79:1087-1093.

14. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257:99-103.

15. Podda S, Ward M, Himelstein A, Richardson C, DelaFlor-Weiss E, Smith L, Gottesman MM, Pastan I, Bank A. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992; 89:9676-9680.

16. Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1994; 1:21-25.

17. Licht T, Haskins M, Henthorn P, Kleiman SE, Bodine DM, Whitwam T, Puck JM, Gottesman MM, Melniczek JR. Drug selection with paclitaxel restores expression of linked interleu-kin-2 receptor gamma chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci 2002; 99:3123-3128.

18. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maan-dag EC, te Riele HP et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.

19. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glyco-protein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-2524.

20. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad SCI USA 1997; 94:4028-4033.

21. Smit JW, Schinkel AH, Weert B, Meijer DK. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br J Pharmacol 1998; 124:416-424.

22. de Lange EC, de Bock G, Schinkel AH, de Boer AG, Breimer DD. BBB transport and P-glycoprotein functionality using MDR1A ( — / —) and wild-type mice. Total brain versus mi-crodialysis concentration profiles of rhodamine-123. Pharm Res 1998; 11:1657-1665.

23. van Asperen J, van Tellingen O, Schinkel AH, Beijnen JH. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. J Pharmacol Exp Ther 1999; 1:329-333.

24. Isola LM, Gordon JW. Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene. Proc Natl Acad Sci USA 1986; 83:9621-9625.

25. James RI, May C, Vagt MD, Studebaker R, McIvor RS. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate. Exp Hematol 1997; 25: 1286-1295.

26. Davis BM, Reese JS, Koc ON, Lee K, Schupp JE, Gerson SL. Selection for G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1997; 57: 5093-5099.

27. Gottesman MM. Multidrug-resistance during chemical carcinogenesis: a mechanism revealed?. J Natl Cancer Inst 1988; 80:1352-1353.

28. Ishizaki K, Tsujimura T, Yawata H, Fujio C, Nakabeppu Y, Sekiguchi M, Ikenaga M. Transfer of the E. coli O6-methyl-guanine methyltransferase gene into repair-deficient human cells and restoration of cellular resistance to N-methyl-N-nitro-N-nitrosoguanidine. Mutat Res 1986; 166:135-141.

29. Zaidi NH, Pretlow TP, O'Riordan MA, Dumenco LL, Allay E, Gerson SL. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 1995; 16:451-456.

30. Liu L, Allay E, Dumenco LL, Gerson SL. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res 1994; 54:4648-4652.

31. Nakatsuru Y, Matsukuma S, Nemoto N, Sugano H, Sekiguchi M, Ishikawa T. O6-methylguanine DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc Natl Acad Sci USA 1993; 90:6468-6472.

32. Becker K, Gregel CM, Kaina B. The DNA repair protein meth-ylguanine-DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea. Cancer Res 1997; 57:3335-3338.

33. May C, Gunther R, McIvor RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 1995; 86:2439-2448.

34. Czerwinski M, Kiem HP, Slattery JT. Human CD34+ cells do not express glutathione S-transferases alpha. Gene Ther 1997; 4:268-270.

35. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal and peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80:2735-2739.

36. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-gly-coprotein expression and function in circulating blood cells from normal volunteer. Blood 1994; 83:2451-2458.

37. McLachlin JR, Eglitis MA, Ueda K, Kantoff PW, Pastan I, Anderson WF, Gottesman MM. Expression of a human com plementary DNA for the human multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 1990; 82:1260-1263. DelaFlor-Weiss E, Richardson C, Ward M, Himelstein A, Smith L, Podda S, Gottesman M, Pastan I, Bank A. Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 1992; 80:3106-3111. Richardson C, Ward M, Podda S, Bank A. Mouse fetal liver cells lack amphotropic retroviral receptors. Blood 1994; 84: 433-439.

Bodine DM, Seidel NE, Gale MS, Nienhuis AW, Orlic D. Efficient retrovirus transduction of mouse pluripotent hemato-poietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor. Blood 1994; 84:1482-1491.

Licht T, Aksentijevich I, Gottesman MM, Pastan I. Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood 1995; 86:111-121.

Ward M, Richardson C, Pioli P, Smith L, Podda S, Goff S, Hesdorffer C, Bank A. Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 1994; 84:1408-1414.

Bertolini F, de Monte L, Corsini C, Lazzari L, Lauri E, Soligo D, Ward M, Bank A, Malavasi F. Retrovirus-mediated transfer of the multidrug resistance gene into human haemopoietic progenitor cells. Br J Haematol 1994; 88:318-324. Omori F, Juopperi T, Chan CK, Chang YN, Phipps S, Nanji S, Zhao Y, Stewart AK, Dube ID. Retroviral-mediated transfer and expression of the multidrug resistance protein 1 gene (MRP1) protect human hematopoietic cells from antineoplas-tic drugs. J Hematother Stem Cell Res 1999; 8:503-514. Flasshove M, Banerjee D, Bertino JR, Moore MA. Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant. Leukemia 1995; 9(Suppl 1):S34-7.

Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 1996; 87:2579-87. Nolta JA, Dao MA, Wells S, Smogorzewska EM, Kohn DB. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc Natl Acad Sci USA 1996; 93:2414-2419. Fruehauf S, Breems DA, Knaan-Shanzer S, Brouwer KB, Haas R, Lowenberg B, Nooter K, Ploemacher RE, Valerio D, Boesen JJ. Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum Gene Ther 1996; 7:1219-1231. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66:85-94. Takebe N, Xu LC, MacKenzie KL, Bertino JR, Moore MA. Methotrexate selection of long-term culture initiating cells following transduction of CD34( +) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther 2002; 9:308-20.

Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 1998; 92:2269-2279.

Sellers SE, Tisdale JF, Agricola BA, Metzger ME, Donahue RE, Dunbar CE, Sorrentino BP. The effect of multidrug-resis-tance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood 2001; 9:1888-1891.

53. Laufs S, Gentner B, Nagy KZ, Jauch A, Benner A, Naundorf S, Kuehlcke K, Schiedlmeier B, Ho AD, Zeller WJ, Fruehauf S. Retroviral vector integration occurs into preferred genomic targets of human bone marrow repopulating cells. Blood 2002; 101:2191-2198.

54. Rund D, Dagan M, Dalyot-Herman N, Kimchi-Sarfaty C, Schoenlein PV, Gottesman MM, Oppenheim A. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions. Hum Gen Ther 1998; 9:649-657.

55. Kimchi-Sarfaty C, Ben-nun-Shaul O, Rund D, Oppenheim A, Gottesman MM. In Vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum Gen Ther 2002; 13:299-310.

56. Lee CGL, Vieira WD, Pastan I, Gottesman MM. An episom-ally maintained MDR1 gene for gene therapy. Hum Gene Ther 2001; 12:945-953.

57. Schiedlmeier B, Schilz AJ, Kuhlcke K, Laufs S, Baum C, Zeller WJ, Eckert HG, Fruehauf S. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum Gene Ther 2002; 13: 233-242.

58. Carpinteiro A, Peinert S, Ostertag W, Zander AR, Hossfeld DK, Kuhlcke K, Eckert HG, Baum C, Hegewisch-Becker S. Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. Int J Cancer 2002; 98:785-792.

59. Hafkemeyer P, Licht T, Pastan I, Gottesman MM. Chemopro-tection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug resistant cancers. Hum Gene Ther 2000; 11:555-565.

60. Dey S, Hafkemeyer P, Pastan I, Gottesman MM. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry 1999; 38:6630-6639.

61. Licht T, Aran JM, Goldenberg SK, Vieira WD, Gottesman MM, Pastan I. Retro-viral transfer of the human multidrug resistance gene to hematopoietic cells: Effects of drug selection and transcript splicing on expression of encoded P-glyco-protein. Hum Gene Ther 1999; 10:2173-2185.

62. Licht T, Goldenberg SK, Vieria WD, Gottesman MM, Pastan I. Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice. Gene Ther 2001; 7: 348-358.

63. Miller AD, Law M-F, Verma IM. Generation of a helper free amphotropic retrovirus that transduces a dominant acting methotrexate resistant dihydrofolate reductase gene. Mol Cell Biol 1985; 5:431-437.

64. Hock RA, Miller AD. Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature 1986; 320:275-277.

65. Li M-X, Banarjee D, Zhao S-C, Schweitzer BI, Mineishi S, Gilboa E, Bertino J. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 1994; 83: 3403-3408.

66. Zhao SC, Li M-X, Banerjee D, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR. Long term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double copy vector retrovirus containing a mutant dihydrofo-late reductase. Cancer Gene Ther 1994; 1:27-33.

67. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate resistant bone marrow. J Exp Med 1987; 166:210-218.

68. Cline MJ, Stang H, Mercola K, Morse L, Ruprecht R, Brown J, SalserW. Gene transfer in intact animals. Nature 1980; 284: 422-425.

69. Vinh DB, Mclvor RS. Selective expression of methotrexate-resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate. J Pharmacol Exp Ther 1993; 267:989-996.

70. Warlick CA, Diers MD, Wagner JE, Mclvor RS. In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J Pharmacol Exp Ther 2002; 300:50-6.

71. James RI, Warlick CA, Diers MD, Gunther R, Mclvor RS. Mild preconditioning and low-level engraftment confer meth-otrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity. Blood 2000; 96:1334-41.

72. Corey CA, DeSilva AD, Holland CA, Williams DA. Serial transplantation of methotrexate resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 1990; 76:337-343.

73. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL, Sorrentino BP. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998; 4: 1136-43.

74. Momparler RL, Eliopoulos N, Bovenzi V, Letourneau S, Greenbaum M, Cournoyer D. Resistance to cytosine arabino-side by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther 1996; 3:331-338.

75. Letourneau S, Greenbaum M, Cournoyer D. Retrovirus-me-diated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum Gene Ther 1996; 7:831-840.

76. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87: 1097-1103.

77. Moreb J, Schweder M, Suresh A, Zucali JR. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 1996; 3:24-30.

78. Allay JA, Dumenco LL, Koc ON, Liu L, Gerson SL. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 1995; 85:3342-3351.

79. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res 1995; 55: 2608-2614.

80. Maze R, Carney JP, Kelley MR, Glassner BJ, Williams DA, Samson L. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemo-therapeutic alkylating agent. Proc Natl Acad Sci USA 1996; 93:206-210.

81. Maze R, Kapur R, Kelley MR, Hansen WK, Oh SY, Williams DA. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine

DNA methyltransferase complementary DNA. J Immunol 1997; 158:1006-1013.

82. Jelinek J, Rafferty JA, Cmejla R, Hildinger M, Chinnasamy D, Lashford LS, Ostertag W, Margison GP, Dexter TM, Fair-bairn LJ, Baum C. A novel dual function retrovirus expressing multi-drug resistance 1 and O6-alkylguanine-DNA-alkyltrans-ferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Ther 1999; 6:1489-93.

83. Rappa G, Lorico A, Hildinger M, Fodstad O, Baum C. Novel bicistronic retroviral vector expressing gamma-glutamylcyst-eine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents. Hum Gene Ther 2001; 12:1785-1796.

84. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottler-Fox M, Leitman SF, Gottes-man MM, Pastan I, Denicoff A, Noone M, Gress R. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Human Gene Therapy 1994; 5:891-911.

85. Hesdorffer C, Antman K, Bank A, Fetell M, Mears G, Begg M. Human MDR1 gene transfer in patients with advanced cancer. Human Gene Ther 1994; 5:1151-1160.

86. Deisseroth AB, Kavanagh J, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther 1994; 5:1507-1522.

87. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortoba-gyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burt-ness B, Edwards C, Bast R, Andreeff M, Champlin R, Deisseroth AB. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996; 93:15346-15351.

88. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Bal-maceda C, Garrett T, Fetell M, Reiss R, Bank A, Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16:165-172.

89. Cowan KH, Moscow JA, Huang H, Zujewski J, Shaughnessy JO, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noon M, Dunbar D, Stein S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A. Paclitaxel chemotherapy following autologous stem cell transplantation and engraftment of hematopoietic cells transduced with a ret-rovirus containing the multidrug resistance cDNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999; 5: 1619-1628.

90. Moscow Ja, Huang H, Carter C, Hines K, Zujewski J, Cusack G, Chow C, Venzon D, Sorrentino B, Chiang Y, Goldspiel B, Leitman S, Read EJ, Abati A, Gottesman MM, Pastan I, Sellers S, Dunbar C, Cowan KH. Engraftment of MDR1 and neoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999; 94:52-61.

91. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coff-man J, Traycoff CM, Bank A, Kato I, Ward M, Williams SD, Hromas R, Robertson MJ, Smith FO, Woo D, Mills B, Srour

EF, Cornetta K. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 105. 652-658.

Metz MZ, Best DM, Kane SE. Harvey murine sarcoma virus/ MDR1 retroviral vectors: efficient virus production and foreign gene transduction using MDR1 as a selectable marker. Virology 1995; 208:634-643.

Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Oster- 106. tag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69:7541-7547.

Eckert HG, ader M, Just U, Hegewisch-Becker S, Grez M, Uhde A, Zander A, Ostertag W, Baum C. High-dose multidrug resistance in primary human hematopoietic progenitor cells 107.

transduced with optimized retroviral vectors. Blood 1996; 88: 3407-3415.

Knipper R, Kuehlcke K, Schiedlmeier B, Hildinger M, Lindemann C, Schilz AJ, Fauser AA, Fruehauf S, Zeller WJ, Oster- 108. tag W, Eckert HG, Baum C. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Ther 2001; 8:239-46.

Baudard M, Flotte TR, Aran JM, Thierry AR, Pastan I, Pang 109. MG, Kearns WG, Gottesman MM. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum Gene Ther 1996;7:1309-1322. 110.

Aksentijevich I, Pastan I, Lunardi-Iskandar Y, Gallo RC, Gottesman MM, Thierry AR. In vitro and in vivo liposome-me-diated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum Gene Ther 1996; 111. 7:1111-1122.

Berger F, Soligo D, Schwarz K, Bossalasco P, Schrezenmeier H, Kubanek B, Deliliers G, Licht T. Efficient retrovirus-me- 112. diated transduction of primitive human peripheral blood progenitor cells in stroma-free suspension culture. Gene Ther 2001; 8: 687-696.

Schiedlmeier B, Kuhlcke K, Eckert HG, Baum C, Zeller WJ, 113. Fruehauf S. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 2000; 114. 95:1237-1248.

Galipeau J, Benaim E, Spencer HT, Blakley RL, Sorrentino BP. A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs. 115.

Hum Gene Ther 1997; 8:1773-1783. Fantz CR, Shaw D, Moore JG, Spencer HT. Retroviral coex-pression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance. Biochem Biophys Res Commun 1998; 243:6-12. 116.

Suzuki M, Sugimoto Y, Tsukahara S, Okochi E, Gottesman MM, Tsuruo T. Retroviral co-expression of two different types of drug-resistance genes to protect normal cells from combination chemotherapy. Clin Cancer Res 1997; 3:947-954. Suzuki M, Sugimoto Y, Tsuruo T. Efficient protection of cells from the genotoxicity of nitrosureas by the retrovirus-mediated 117.

transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1. Mutat Res 1998; 401:133-141. Letourneau S, Greenbaum M, Cournoyer D. Retrovirus-me-diated gene transfer of rat glutathione S-transferase Yc confers 118.

in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum Gene Ther 1996; 7:831-840.

Sugimoto Y, Hrycyna CA, Aksentijevich I, Pastan I, Gottes-man MM. Coexpression of a multidrug-resistance gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic messenger RNA in a retrovirus vector allows selective killing of MDR1-transduced cells. Clinical Cancer Res 1995b; 1:447-457.

Sugimoto Y, Sato S, Tsukahara S, Suzuki M, Okochi E, Gottesman MM, Pastan I, Tsuruo T. Co-expression of a multidrug resistance gene (MDR1) and Herpes simplex virus thymidine kinase gene in a bicistronic vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in mice. Cancer Gene Ther 1997; 4:51-58. Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP. Effects of retroviral-mediated MDR1 expression on hema-topoietic stem cell self-renewal and differentiation in culture. Ann N Y Acad Sci 1999; 872:125-40. Mineishi S, Nakahara S, Takebe N, Banerjee D, Zhao SC, Bertino JR. Co-expression of the herpes simplex virus thymi-dine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Gene Ther 1997; 46:570-576.

Zhao RC, McIvor RS, Griffin JD, Verfaillie CM. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood 1997; 90:4687-4698.

Xu LC, Kluepfel-Stahl S, Blanco M, Schiffmann R, Dunbar

C, Karlsson S. Growth factors and stromal support generate very efficient retroviral transduction of peripheral blood CD34 + cells from Gaucher patients. Blood 1995; 86:141-146. Havenga M, Fisher R, Hoogerbrugge P, Roberts B, Valerio

D, van Es HH. Development of safe and efficient retroviral vectors for Gaucher disease. Gene Ther 1997; 4:1393-1400. Aran JM, Gottesman MM, Pastan I. Drug-selected coexpres-sion of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA 1994; 91: 3176-3180.

Aran JM, Licht T, Gottesman MM, Pastan I. Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy. Human Gene Ther 1996a; 7:2165-2175. Havenga M, Valerio D, Hoogerbrugge P, Es H. In vivo metho-trexate selection of murine hemopoietic cells transduced with a retroviral vector for Gaucher disease. Gene Ther 1999; 6: 1661-9.

Sugimoto Y, Aksentijevich I, Murray GJ, Brady RO, Pastan I, Gottesman MM. Retroviral co-expression of a multidrug resistance gene (MDR1) and human a-galactosidase A for gene therapy of Fabry Disease. Human Gene Therapy 1995; 6:905-915.

Sokolic RA, Sekhsaria S, Sugimoto Y, Whiting-Theobald N, Linton GF, Li F, Gottesman MM, Malech HL. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. [Rapid Communication] Blood 1996; 87:42-50.

Sugimoto Y, Tsukahara S, Sato S, Suzuki M, Nunoi H, Malech HL, Gottesman MM, Tsuruo T. Drug-selected co-expression of P-gklycoprotein and gp91 in vivo from an MDR1-bicis-tronic retrovirus vecter pHa-MDR-IRES-gp91. J Gene Med 2002; 5:366-376.

Zhou Y, Aran J, Gottesman MM, Pastan I. Co-expression of human adenosine deaminase and multidrug resistance using a bicistronic retroviral vector. Hum Gene Ther 1998; 9: 287-293.

119. Kleiman SE, Pastan I, Puck JM, Gottesman MM. Characterization of an MDR1 retroviral bicistronic vector for correction of X-linked severe combined immunodeficiency. Gene Ther 1998; 5:671-676.

120. Saylors RL, Wall DA. Expression of human alpha 1 antitrypsin in murine hematopoietic cells in vivo after retrovirus-mediated gene transfer. Mol Genet Metab 1998; 63:198-204.

121. Germann UA, Chin K-V, Pastan I, Gottesman MM. Retroviral transfer of a chimeric multidrug resistance-adenosine deami-nase gene. FASEB J 1990; 4:1501-1507.

122. Pfutzner W, Terunuma A, Tock CL, Snead EK, Kolodka TM, Gottesman MM, Taichman L, Vogel JC. Topical colchicines selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo. Proc Natl Acad Sci USA 2002; 99:13096-13101.

123. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB. a-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 1997; 94: 2540-2544.

124. Aran JM, Gottesman MM, Pastan I. Construction and characterization of bicistronic vectors encoding the multidrug transporter and ß-galactosidase or green fluorescent protein. Cancer Gene Ther 1998; 5:195-206.

125. Germann UA, Gottesman M, Pastan I. Expression of a multid-rug resistance-adenosine deaminase fusion gene. J Biol Chem 1989; 264:7418-7424.

126. Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988; 334:320-325.

127. Trono D, Pelletier J, Sonenberg N, Baltimore D. Translation in mammalian cells of a gene linked to the poliovirus 5'-non-coding region. Science 1988; 41:445-448.

128. Adam MA, Ramesh N, Miller AD, Osborne WA. Internal initiation of translation in retroviral vector carrying picornavirus 5' nontranslated regions. J Virology 1991; 65:4985-4990.

129. Kaufman RJ, Davies MV, Wasley LC, Michnick D. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res 1991; 19:4485-4490.

130. Lee CGL, Jeang K-T, Martin MA, Pastan I, Gottesman MM. Efficient long term co-expression of a hammerhead ribozyme targeted to the U5 region of HIV-1 LTR by linkage to the multidrug-resistance gene. Antisense Nucleic Acid Drug Dev 1997; 7:511-522.

131. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988; 85:4486-4490.

132. Zhang S, Sugimoto Y, Shoshani T, Pastan I, Gottesman MM. A pHaMDR-DHFR bicistronic expression system for muta-tional analysis of P-glycoprotein. Methods Enzymol 1998; 292:474-480.

133. Wang J, Chen Z, Xia X, Lu D, Xue J, Ruan C. Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR into human umbilical cord blood CD34( +) cells. Leuk Res 2002; 26:281-288.

134. Sugimoto Y, Aksentijevich I, Gottesman M, Pastan I. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Bio/Technology 1994; 12:694-698.

135. Hellen CU, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Gene Dev 2001; 15:1593-1612.

136. Toyoda H, Koide N, Kamiyama M, Tobita K, Mizumoto K, Imura N. Host factors required for internal initiation of translation on poliovirus RNA. Arch Virol 1994; 138:1-15.

137. Brown EA, Zajac A, Lemon S. In vitro characterization of an internal ribosomal entry site present within the 5' nontranslated region of hepatitis A virus RNA: comparison with the IRES of encephalomyocarditis virus. J Virology 1994; 68:1066-1074.

138. Borman AM, Bailly J, Girard M, Kean K. Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. Nucleic Acid Res 1995; 23:3656-3663.

139. Sachs A. Cell cycle-dependent translation initiation: IRES elements prevail. Cell 2000; 101:243-245.

140. Mauro VP, Edelman G. The ribosome filter hypothesis. Proc Natl Acad Sci USA 2002; 99:12031-12036.

141. Chappell SA, Edelman GM, Mauro V. A 9-nt segment of a cellular mRNA can function as an internal ribosome entry site and when present in linked multiple copies greatly enhances IRES activity. Proc Natl Acad Sci USA 2000; 97:1536-1541.

142. Wong ET, Ngoi SM, Lee CG. Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Ther 2002; 9:337-344.

143. Aran JM, Germann UA, Gottesman MM, Pastan I. Construction and characterization of a selectable multidrug resistance-glucocerebrosidase fusion gene. Cytokines and Molecular Therapy 1996; 2:47-57.

144. Blaese RM. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. Ped Res 1993; 33(suppl):S49-S55.

145. Kantoff PW, Kohn DB, Mitsuya H, Armentano D, Sieberg M, Zweibel JA, Eglitis MA, McLachlin JR, Wiginton DA, Hutton JJ, Horowitz SD, Gilboa E, Blaese RM, Anderson WF. Correction of adenosine deaminase deficiency in human T and B cells using retroviral gene transfer. Proc Natl Acad Sci USA 1986; 83:6563-67.

146. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1990; 87:2211-2215.

147. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994; 11:517-521.

148. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995; 2:357-362.

149. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB, Carter BJ. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 1993; 90:10613-10617.

150. Flotte TR, Afione SA, Solow R, Drumm ML, Markakis D, Guggino WB, Zeitlin PL, Carter BJ. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993; 268: 3781-3790.

151. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Mal-ley KL, During MJ. Long-term gene expression and pheno-typic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8:148-154.

152. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93:14082-14087.

Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA. Persistent and therapeutic concentrations of human factor 1X in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16:270-276. Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 1997; 144:113-124.

Tsui LC, Breitman ML, Siminovitch L, Buchwald M. Persistence of freely replicating SV40 recombinant molecules carrying a selectable marker in permissive simian cells. Cell 1982; 30:499-508.

Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313:812-815.

Cooper MJ, Miron S. Efficient episomal expression vector for human transitional carcinoma cells. Hum Gene Ther 1993; 4: 557-566.

Milanesi G, Barbanti-Brodano G, Negrini M, Lee D, Corallini A, Caputo A, Grossi MP, Ricciardi RP. BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli. Mol Cell Biol 1984; 4: 1551-1560.

Sabbioni S, Negrini M, Rimessi P, Manservigi R, Barbanti-Brodano G. A BK virus episomal vector for constitutive high expression of exogenous cDNAs in human cells. Arch Virol 1995; 140:335-339.

Mortimer EA, Lepow ML, Gold E, Robbins FC, Burton GJ, Fraumeni JF. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 1981; 305: 1517-1518.

Shah K, Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol 1976; 103:1-12. Tooze J. DNA Tumor Viruses. New York: Cold Spring Harbor Laboratory, 1981.

Khalili K. Human Polyomaviruses. New York: Wiley-Liss, Inc, 2001.

Norkin LC. Simian virus 40 infection via MHC class I molecules and caveolae. Immunol rev 1999; 168:13-22. Norkin LC. Caveolae in the uptake and targeting of infectious agents and secreted toxins. Adv Drug Delivery 2001; 49: 301-315.

Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001; 3:473-483. Norkin LC, Anderson HA, Wolfrom SA, Oppenheim A. Ca-veolar endocytosis of simian virus 40 is followed by brefeldin A-sensitive transport to the endoplasmic reticulum, where the virus disassembles. J Virol 2002; 76:5156-5166. Chia W, Rigby PW. Fate of viral DNA in nonpermissive cells infected with simian virus 40. Proc Natl Acad Sci USA 1981; 78:6638-6642.

Strayer DS, Zern MA, Chowdhury JR. What can SV40-derived vectors do for gene therapy?. Curr Opin Mol ther 2002; 4: 313-323.

GarceaRL. SV40: a human pathogen?. Dis Markers 2001; 17: 149-151.

Klein G, Powers A, Croce C. Association of SV40 with human tumors. Oncogene 2002; 21:1141-1149.

Oppenheim A, Pelege E, Fibach E, Rchmilewitz EA. Efficient introduction of plasmid DNA into human hemopoietic cells by encapsidation in simian virus 40 pseudovirions. Proc Natl

Acad Sci USA 1986; 83:6925-6929.

Strayer DS, Pomerantz RJ, Yu M, Roxenzweig M, BouHam-

dan S, Yurasov R, Johnson P, Goldstein H. Efficient gene transfer to hematopoietic progenitor cells using SV40-deiived vectors. Gene Ther 2000; 7:886-895.

174. Mellon P, parker V, Gluzman Y, Maniatis T. Identification of DNA sequences required for transcription of the human alpha 1-globin gene in a new SV40 host-vector system. Cell 1981; 27:279-278.

175. Oppenheim A, Peleg A, Rachmilewitz EA. Efficient introduction and transient expression of exogenous genes in human hemopoietic cells. Ann NY Acad Sci 1987; 511:418-427.

176. Dalyot-Herman N, Ben-nun-Shaul O, Gordon-Shaag A, Oppenheim A. The simian virus 40 packaging signal ses is composed of redundant DNA elements which are partly interchangeable. J Mol Biol 1996; 259:69-80.

177. Strayer DS, Kondo R, Milano J, Duan LX. Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Ther 1997; 4:219-225.

178. Dalyot-Herman N, Rund D, Oppenheim A. Expression of beta-globin in primary erythroid progenitors of beta-thalassemia patients using an SV40-based gene delivery system. J Hema-tother Stem Cell Res 1999; 8:593-599.

179. Strayer DS. Gene delivery to human hematopoietic progenitor cells to address inherited defects in the erythroid cellular lineage. J Hematother Stem Cell Res 1999; 8:573-574.

180. Strayer DS. Gene therapy using SV40-derived vectors: what does the future hold?. J Cell Physiol 1999; 181:375-384.

181. Strayer DS. Effective gene transfer using viral vectors based on SV40. Methods Mol Biol 2000; 133:61-74.

182. Fang B, Koch P, Bouvet M, Ji L, Roth JA. A packaging system for SV40 vectors without viral coding sequences. Anal Bio-chem 1997; 254:139-143.

183. Sandalon Z, Dalyot-Herman N, Oppenheim AB, Oppenheim A. In vitro assembly of SV40 virions and pseudovirions: vector development for gene therapy. Hum Gene Ther 1997; 8: 843-849.

184. Sandalon Z, Oppenheim A. Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 1997; 237:414-421.

185. Wrobel B, Yosef Y, Oppenheim AB, Oppenheim A. Production and purification of SV40 major capsid protein (VP!) in Escherichia coli strains deficient for the GroELS chaperone machine. J Biotechnol 2000; 84:285-289.

186. Sandalon Z, Oppenheim A. Production of SV40 proteins in insect cells and in vtiro packaging of virions and pseudoviri-ons. Methods Mol Biol 2001; 165:119-128.

187. Kimchi-Sarfaty C, Arora M, Sandalon Z, Oppenheim A, Gottesman MM. High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum Gene Ther 2003; in press.

188. Kieff E, Liebowitz D. Epstein Barr Virus and its replication. In: Fields BN, Knipe DM, Eds. Virology. New York: Raven, 1990:1921-1958.

189. Margolskee RF. Epstein-Barr virus based expression vectors. Curr Top Microbiol Immunol 1992; 158:67-95.

190. Sarasin A. Shuttle vectors for studying mutagenesis in mammalian cells. Journal of Photochemistry and Photobiology B: Biology 1989; 3:143-155.

191. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375:685-688.

192. Haase SB, Calos MP. Replication control of autonomously replicating human sequences. Nucleic Acids Res 1991; 19: 5053-5058.

193. Sun TQ, Fernstermacher DA, Vos JM. Human artificial epi-somal chromosomes for cloning large DNA fragments in human cells [published erratum appears in. Nat Genet. Nat Genet 1994; 8:33-41].

194. Banerjee S, Livanos E, Vos JM. Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. Nat Med 1995; 1: 1303-1308.

195. Lee CGL, Vieira WD, Pastan I, Gottesman MM. Delivery Systems for the MDR1 gene. In: Boulikas T, Ed. Gene Therapy and Molecular Biology, 1998:241-251.

196. DiMaio D, Treisman R, Maniatis T. Bovine papillomavirus vector that propagates as a plasmid in both mouse and bacterial cells. Proc Natl Acad Sci USA 1982; 79:4030-4034.

197. Mecsas J, Sugden B. Replication of plasmids derived from bovine papilloma virus type 1 and Epstein-Barr virus in cells in culture. Annu Rev Cell Biol 1987; 3:87-108.

198. Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Grignani F, Lanfrancone L, Peschle C, Nolan GP, Pelicci PG. High-efficiency gene transfer and selection of human he-matopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 1998; 58:14-19.

199. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7:1405-1413.

200. Feng M, Jackson WH, Goldman CK, Rancourt C, Wang M, Dusing SK, Siegal G, Curiel DT. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector [see comments]. Nat Biotechnol 1997; 15:866-70.

201. Wang S, Di S, Young WB, Jacobson C, Link CJ. A novel herpesvirus amplicon system for in vivo gene delivery. Gene Ther 1997; 4:1132-1141.

202. Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA. Gene transfer into hepato-cytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 1997; 3:813-825.

203. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases [comment]. Proc Natl Acad Sci USA 1996; 93:11421-11425.

204. Hirai H, Satoh E, Osawa M, Inaba T, Shimazaki C, Kinoshita S, Nakagawa M, Mazda O, Imanishi J. Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem Biophys Res Commun 1997; 241:112-118.

205. Satoh E, Osawa M, Tomiyasu K, Hirai H, Shimazaki C, Oda Y, Nakagawa M, Kondo M, Kinoshita S, Mazda O, Imanishi J. Efficient gene transduction by Epstein-Barr-virus-based vectors coupled with cationic liposome and HVJ-liposome. Biochem Biophys Res Commun 1997; 238:795-799.

206. Krysan PJ, Haase SB, Calos MP. Isolation of human sequences that replicate autonomously in human cells. Mol Cell Biol 1989; 9:1026-1033.

207. Krysan PJ, Calos MP. Epstein-Barr virus-based vectors that replicate in rodent cells. Gene 1993; 136:137-143.

208. Calos MP. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet 1996; 12:463-466.

209. Jankelevich S, Kolman JL, Bodnar JW, Miller G. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain. EMBO J 1992; 11:1165-1176.

210. Wohlgemuth JG, Kang SH, BulboacaGH, Nawotka KA, Calos MP. Long-term gene expression from autonomously replicating vectors in mammalian cells. Gene Ther 1996; 3:503-512.

211. DePamphilis ML. Eukaryotic replication origins In DePam-philis ML, Ed. DNA replication in eukaryotic cells. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1996: 983-1004.

212. Willard HF, Waye JS. Hierarchical order in chromosome-specific human alpha satellite DNA. Trends Genet 1987; 3: 192-198.

213. Bloom K. The centromere frontier: kinetochore components, microtubule-based motility, and the CEN-value paradox. Cell 1993; 73:621-624.

214. Harrington JJ, van Bokkelen G, Mays RW, Gustashaw K, Willard HF. Formation of de novo centromeres and construction of first-generation human artificial microchromosomes [see comments]. Nat Genet 1997; 15:345-355.

215. Philip R, Liggitt D, Philip M, Dazin P, Debs R. Efficient trans-fection of T lymphocytes in adult mice. J Biol Chem 1993; 268:16087-16090.

216. Philip R, Brunette E, Kilinski L, Murugesh D, McNally M, Ucar K, Rosenblatt J, Okarama TB, Lebkowski JS. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associ-ated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 1994; 14:2411-2418.

217. Bruggemann EP, Currier SJ, Gottesman MM, Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992; 267:21020-21026.

218. Greenberger LM. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-Terminal to, transmembrane domain-6 and domain-12. J Biol Chem 1993; 268:11417-11425.

219. Greenberger LM, Lisanti CJ, Silva JT, Horwitz SB. Domain mapping of the photoaffinity drug-binding sites in P-glycopro-tein encoded mouse mdr1b. J Biol Chem 1991; 266: 20744-20751.

220. Morris DI, Greenberger LM, Bruggemann EP, Cardarelli CO, Gottesman MM, Pastan I, Seamon KB. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. Mol Pharmacol 1994; 46:329-337.

221. Zhang X, Collins KI, Greenberger LM. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycopro-tein encoded by MDR1. J Biol Chem 1995; 270:5441-5448.

222. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6:610-617.

223. Devine SE, Ling V, Melera PW. Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci USA 1992; 89: 4564-4568.

224. Ma JF, Grant G, Melera PW. Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal. Mol Pharmacol 1997; 51:922-930.

225. Loo TW, Clarke DM. Functional consequences of phenylala-nine mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 1993; 268:19965-19972.

226. Loo TW, Clarke DM. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 1994b; 33:14049-14057.

227. Hanna M, Brault M, Kwan T, Kast C, Gros P. Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning. Biochemistry 1996; 35:3625-3635.

228. Choi K, ChenC-J, Kriegler M, RoninsonIB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1989; 53:519-529.

229. Currier SJ, Kane SE, Willingham MC, Cardarelli CO, Pastan I, Gottesman MM. Identification of residues in the first cyto-

plasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. J Biol Chem 1992; 267:25153-25159.

230. Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, Ueda K. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989; 162:224-231.

231. Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND, Roninson IB. Molecular basis of preferential resistance to col-chicine in multidrug-resistant human cells conferred by Gly to Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 1990; 87:7225-7229.

232. Loo TW, Clarke DM. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J Biol Chem 1994; 269:7243-7248.

233. Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Du-montet C, Sikic BI. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem 1997; 272:5974-5982.

234. Shoshani T, Zhang S, Dey S, Pastan I, Gottesman MM. Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-DHFR bicistronic expression system. Mil Pharmacol 1998; 54:623-630.

235. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 1989; 35:105-115.

236. Yang JM, Goldenberg S, Gottesman MM, Hait WN. Characteristics of P388/VMDRC0.4, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res 1994; 54: 730-737.

237. Hafkemeyer P, Dey S, Ambudkar SV, Hrycyna CA, Pastan I, Gottesman MM. Contribution to substrate specificity and transport of non-conserved residues in the transmembrane domain 12 of the human P-glycoprotein. Biochemistry 1998; 37: 16400-16409.

238. Rahman Z, Kavanagh J, Champlin R, Giles R, Hannia E, Fu S, Zu Z, Hena R, Holmes F, Kudelka A, Claxton D, Versch-raegen C, Gajewski J, Andreeff M, Himeld S, Bersonson R, Ellerson D, Calvert L, Mechetner E, Holfmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 1998; 11:2717-2721.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment